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 Supplementary Table 1: Odds ratio of difficulty gripping heavy objects by statin use and 25-hydroxyvitamin D status, adjusted for inflammatory markers, BMI, knee OA, 
education, SEC and smoking (n= 1556). 
  
  
 
  
Difficulty gripping heavy 
objects 
  
 
  
 
  
 
Model A (Sex adjusted 
only) 
  
Model B (Mutually adjusted with 
interaction) 
  
Model C = Model B + 
inflammatory markers 
  
Model D = Model C + BMI & 
Knee OA 
  
Model E = Model D + SEC, 
education & smoking† 
  
 
OR 95% CI p value   OR 95% CI p value   OR 95% CI p value   OR 95% CI p value   OR 95% CI p value 
 
Statin Use 1.2 (0.9,1.7) 0.211   
   
  
   
  
   
  
    
25-hydroxyvitamin D 
 
Overall effect 
  
0.149   
 
Normal >20 ng/l 1.0 
  
  
 
Insufficient 13-20ng/l 0.9 (0.6,1.3) 
 
  
 
Deficient <13ng/l 1.2 (0.9,1.7) 
 
  
 
Statin Use (vs non use) by 25-hydroxyvitamin D  (Interaction) 
 
Statin Use in those 
with Normal >20 ng/l     
  0.7 (0.3,1.3) 0.260   0.6 (0.3,1.3) 0.236   0.6 (0.3,1.3) 0.250   0.6 (0.3,1.3) 0.213 
 
Statin Use in  
Insufficient 13-20ng/l    
  1.8 (1.0,3.2) 0.049   1.7 (0.9,3.0) 0.082   1.5 (0.8,2.7) 0.187   1.4 (0.7,2.5) 0.286 
 
Statin Use in Deficient 
<13ng/l    
  1.3 (0.8,2.2) 0.312   1.3 (0.7,2.1) 0.364   1.2 (0.7,2.0) 0.563   1.1 (0.6,1.8) 0.809 
 
IL6 (log pg/ml) 
   
  
   
  1.2 (0.9,1.5) 0.132   1.2 (0.9,1.5) 0.164   1.1 (0.9,1.4) 0.232 
 
CRP (log mg/l) 
   
  
   
  1.2 (1.0,1.5) 0.019   1.2 (1.0,1.4) 0.065   1.1 (1.0,1.4) 0.140 
 
BMI at 53 (per 1 kg/m2 
increase)    
  
   
  
   
  1.0 (1.0,1.0) 0.465   1.0 (1.0,1.0) 0.551 
 
Knee OA at 53 (Yes vs 
No)    
  
   
  
   
  1.9 (1.3,2.9) 0.002   1.9 (1.2,2.8) 0.003 
 
Sex (Men vs Women) 
   
  5.2 (3.8,7.2) <0.001   5.2 (3.8,7.2) <0.001   5.0 (3.6,7.0) <0.001   5.0 (3.6,7.0) <0.001 
 
† SEC, education & smoking not shown 
*  p-value=0.093 for the  interaction between statin use and 25-hydroxyvitamin D in Model B (formally tested using a likelihood ratio test comparing models with and without an 
interaction between 25-hydroxyvitamin D and statin use) 
 
Supplementary Table 2: Difference in mean grip strength (kg) by statin use and 25-hydroxyvitamin D  status, adjusted for inflammatory markers, BMI, knee OA, education, 
SEC and smoking (n= 1556). 
  
  
 
  Grip Strength   
 
  
 
  
 
Model A (Sex adjusted only)   
Model B (Mutually adjusted with 
interaction) 
  
Model C = Model B + 
inflammatory markers 
  
Model D = Model C + BMI & 
Knee OA 
  
Model E = Model D + SEC, 
education & smoking† 
  
 
Regression coefficient 95% CI 
p 
value 
  
Regression 
coefficient 
95% CI p value   
Regression 
coefficient 
95% CI p value   
Regression 
coefficient 
95% CI p value   
Regression 
coefficient 
95% CI p value 
 
Statin Use -0.2 ( -1.4, 1.1) 0.764   
   
  
   
  
   
  
    
25-hydroxyvitamin D 
 
Overall effect 
  
0.426   
 
Normal >20 ng/l 0 
  
  
 
Insufficient Vit D 
13-20ng/l 
0.0 ( -1.3, 1.2) 
 
  
 
Deficient <13ng/l -0.7 ( -1.9, 0.5) 
 
  
 
Statin Use (vs non use) by 25-hydroxyvitamin D  (Interaction) 
 
Statin Use in 
those with 
Normal >20 ng/l  
   
  -0.9 ( -3.3, 1.5) 0.449   -0.8 
( -3.1, 
1.6) 
0.518   -1.2 
( -3.5, 
1.2) 
0.328   -1.1 
( -3.4, 
1.3) 
0.367 
 
Statin Use in  
Insufficient 13-
20ng/l 
   
  0.7 ( -1.4, 2.8) 0.512   1.0 
( -1.1, 
3.1) 
0.365   0.9 
( -1.2, 
3.1) 
0.398   1.2 
( -1.0, 
3.3) 
0.287 
 
Statin Use in 
Deficient <13ng/l    
  -0.3 ( -2.4, 1.7) 0.746   -0.2 
( -2.3, 
1.8) 
0.819   -0.4 
( -2.5, 
1.6) 
0.670   -0.3 
( -2.3, 
1.7) 
0.784 
 
IL6 (log pg/ml) 
   
  
   
  -0.9 
( -1.8, -
0.1) 
0.023   -1.0 
( -1.8, -
0.2) 
0.015   -0.9 
( -1.8, -
0.1) 
0.023 
 
CRP (log mg/l) 
   
  
   
  -0.5 
( -1.2, 
0.1) 
0.124   -0.6 
( -1.3, 
0.1) 
0.072   -0.5 
( -1.2, 
0.2) 
0.160 
 
BMI at 53 (per 1 
kg/m2 increase)    
  
   
  
   
  0.1 
( 0.0, 
0.3) 
0.017   0.2 
( 0.0, 
0.3) 
0.010 
 
Knee OA at 53 
(Yes vs No)    
  
   
  
   
  -2.3 
( -4.0, -
0.5) 
0.013   -2.1 
( -3.8, -
0.3) 
0.023 
 
Sex (Men vs 
Women)    
  -19.2 
(-20.2,-
18.2) 
<0.001   -19.2 
(-20.2,-
18.2) 
<0.001   -19.1 
(-20.1,-
18.1) 
<0.001   -18.8 
(-19.8,-
17.7) 
<0.001 
 
† SEC, education & smoking not shown 
 
*  p-value=0.585 for the  interaction between statin use and 25-hydroxyvitamin D in Model B (formally tested using a likelihood ratio test comparing models with and without an 
interaction between 25-hydroxyvitamin D and statin use) 
 
 
 
 
 
Supplementary Figure 1: Interaction effect of statin use and log 25-hydroxyvitamin D  (modelled 
continuously) in association with gripping heavy objects (p-value for interaction=0.41).
 
